Three‐Year Safety Results of SAR422459 (EIAV‐ABCA4) Gene Therapy in Patients With ABCA4‐Associated Stargardt Disease: An Open‐Label Dose‐Escalation Phase I/IIa Clinical Trial, Cohorts 1‐5: Results of Gene Therapy in Patients With Stargardt Disease

Maria A. Parker, Laura R. Erker, Isabelle Audo, Dongseok Choi, Saddek Mohand-Said, Kastytis Sestakauskas, Patrick Benoit, Terence Appelqvist, Melissa Krahmer, Caroline Ségaut-Prévost, Brandon J. Lujan, Ambar Faridi, Elvira N. Chegarnov, Peter N. Steinkamp, Cristy Ku, Mariana Matioli da Palma, Pierre Olivier Barale, Sarah Ayelo-Scheer, Andreas Lauer, Tim StoutDavid J. Wilson, Richard G. Weleber, Mark E. Pennesi, José Alain Sahel, Paul Yang

Research output: Contribution to journal › Article › peer-review

20 Scopus citations

Fingerprint

Dive into the research topics of 'Three‐Year Safety Results of SAR422459 (EIAV‐ABCA4) Gene Therapy in Patients With ABCA4‐Associated Stargardt Disease: An Open‐Label Dose‐Escalation Phase I/IIa Clinical Trial, Cohorts 1‐5: Results of Gene Therapy in Patients With Stargardt Disease'. Together they form a unique fingerprint.

Medicine & Life Sciences